Foresee Pharmaceuticals (6576.TWO)

Executive Summary

Foresee Pharmaceuticals is a Taiwan- and US-based biopharmaceutical company (TPEx: 6576) focused on developing innovative small molecule and drug delivery technologies to improve patient comfort, compliance, and convenience. With a valuation of approximately $12.7B, the company targets unmet medical needs through a pipeline of novel therapies, leveraging its proprietary delivery platforms to enhance therapeutic outcomes. Foresee's dual headquarters in San Diego and Taipei enable access to both Asian and Western markets, positioning it for global expansion. The company's mission-driven approach aims to deliver transformative treatments that ultimately provide cures, supported by a robust intellectual property portfolio and strategic partnerships. Key near-term value drivers include advancement of lead candidates through clinical trials and potential regulatory milestones.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 topline data for lead product FP-001 (prostate cancer)70% success
• Q4 2026NDA submission for FP-002 (pain management)60% success
• Q2 2026Strategic licensing deal for drug delivery platform50% success